U.S. Government Awards Emergent BioSolutions $52.7M Contract for Smallpox/Mpox Vaccine
EBS sits 51% above its 52-week low of $5.615 on elevated volume (2.6× avg).
Summary
Emergent BioSolutions secured a $52.7 million contract modification from the U.S. government to supply its ACAM2000® smallpox and mpox vaccine. This is a material contract, representing approximately 12% of the company's current market capitalization. It follows a series of recent positive developments for Emergent, including a $64.5 million contract modification in May and several strategic partnerships and debt refinancing in April, underscoring the company's consistent role in biodefense preparedness.
At the time of this announcement, EBS was trading at $8.46 on NYSE in the Life Sciences sector, with a market capitalization of approximately $440.1M. The 52-week trading range was $5.62 to $14.06. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.